Enfusion Temettü

Temettü kriter kontrolleri 0/6

Enfusion şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	0.8%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	US$0.034
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Dec 02

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Nov 08

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Oct 31

Enfusion Faces Cross-Currents In Investment Management Software Market

Aug 24

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 11

Enfusion: Multiple Catalysts

Jun 20

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Mar 08

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Feb 08

Enfusion brings on Shift4 Payments' Brad Herring as CFO

Dec 19

Enfusion Expands Offerings As Revenue Growth Decelerates

Oct 31

Enfusion, Inc. (NYSE:ENFN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Oct 18

Enfusion gains after takeover report

Aug 31

Enfusion gets new interim CEO

Aug 22

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Aug 12

Enfusion: A Compelling Financial SaaS Company

Jun 24

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ENFN şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ENFN şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Enfusion Piyasaya Karşı Temettü Getirisi

ENFN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ENFN)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Software)	0.8%
Analist tahmini (ENFN) (3 yıla kadar)	0%

Önemli Temettü: ENFN şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ENFN şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ENFN şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ENFN herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Enfusion Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

New minor risk - Shareholder dilution

Enfusion, Inc Announces Executive Appointments

Enfusion, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Enfusion Reportedly in Talks with Investment Bankers to Evaluate Options, Include Potential Sale

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Enfusion: Growth Should Accelerate In Coming Quarters

Investors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings Quality

Consensus EPS estimates increase by 51%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Enfusion, Inc. Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and Flexibility

New minor risk - Shareholder dilution

Enfusion, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Chief People Officer recently sold US$234k worth of stock

Chief People Officer notifies of intention to sell stock

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating

New minor risk - Shareholder dilution

Chief People Officer recently sold US$325k worth of stock

Chief People Officer notifies of intention to sell stock

Consensus EPS estimates fall by 38%

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Enfusion, Inc., Annual General Meeting, Jun 13, 2024

Enfusion, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 20%, revenue upgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Is Now An Opportune Moment To Examine Enfusion, Inc. (NYSE:ENFN)?

New minor risk - Shareholder dilution

Now 20% undervalued after recent price drop

Capital Allocation Trends At Enfusion (NYSE:ENFN) Aren't Ideal

Enfusion, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 22% undervalued

New minor risk - Shareholder dilution

Enfusion, Inc. Elevates Valeria Gutowski to Chief Accounting Officer

Enfusion: Product Is Sticky And Industry Is Huge

Calculating The Fair Value Of Enfusion, Inc. (NYSE:ENFN)

CEO & Director recently sold US$1.0m worth of stock

New minor risk - Shareholder dilution

CEO & Director recently sold US$1.5m worth of stock

CEO & Director notifies of intention to sell stock

Investors Appear Satisfied With Enfusion, Inc.'s (NYSE:ENFN) Prospects As Shares Rocket 28%

Managing Partner recently sold US$9.9m worth of stock

Enfusion, Inc. Appoints Neal Pawar as Chief Operating Officer, Effective November 27, 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 32%

Enfusion: Still Bullish Considering Q3 EBITDA Beat

Why Enfusion, Inc. (NYSE:ENFN) Could Be Worth Watching

Enfusion, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Shareholder dilution

Enfusion Faces Cross-Currents In Investment Management Software Market

Enfusion, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.0% to US$10.43

Enfusion, Inc. Appoints Andi Woolass as Head of Partnerships and Alliances for EMEA

Enfusion Reportedly Draws Takeover Interest from Private Equity, Irenic Capital

Enfusion: Multiple Catalysts

Now 21% undervalued after recent price drop

Price target decreased by 7.1% to US$11.21

Chief Technology Officer recently sold US$396k worth of stock

Chief Technology Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Chief Technology Officer recently sold US$126k worth of stock

Chief Technology Officer notifies of intention to sell stock

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued after recent price drop

Insider recently sold US$20m worth of stock

Full year 2022 earnings released: US$0.15 loss per share (vs US$2.26 loss in FY 2021)

Enfusion, Inc.'s (NYSE:ENFN) Intrinsic Value Is Potentially 32% Above Its Share Price

Enfusion, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Here's Why We're Not At All Concerned With Enfusion's (NYSE:ENFN) Cash Burn Situation

Enfusion, Inc. Names Michael Spellacy as Board Chair and Non-Executive Director

Price target decreased to US$12.80

Enfusion, Inc. Names Oleg Movchan as Chief Executive Officer

Enfusion, Inc. Appoints Brad Herring as Chief Financial Officer